Clinical Trial Update: Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating MT-6548 in hemodialysis patients with CKD-related anemia completed; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• MT-6548

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Anemia; Hemodialysis Dependent Chronic Kidney Disease | Phase 3 | Status: COMPLETED | Results posted: 2021-05-07